Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

janssen_latest_logo_on_sign_closer

FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019
Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …

News
janssen_latest_logo_on_sign_closer

FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer

September 19, 2019
Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …

News
janssen_latest_logo_on_sign_closer

Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019
Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …

News
shutterstock_512649

Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%

August 1, 2019
Sales and Marketing Alligator Bioscience, Janssen, pahrma

Janssen has decided to hand back the rights to an experimental CD40 agonistic antibody to Alligator Bioscience as it reassesses …

News
janssen_latest_logo_on_sign

Janssen secures two positive CHMP opinions for Imbruvica label expansions

July 1, 2019
Sales and Marketing CHMP, EMA, Europe, Janssen, imbruvica, pharma

Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo approved by FDA in transplant-ineligible multiple myeloma patients

June 28, 2019
Medical Communications, Sales and Marketing Janssen, darzalex, mutiple myeloma, pharma

Janssen’s Darzalex (daratumumab) has secured FDA approval in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …

News
shutterstock_159488225

Darzalex combo makes strong Phase 3 showing in multiple myeloma

June 4, 2019
Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma

Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …

News
janssen_latest_logo_on_sign

Janssen’s Imbruvica shows superiority in Phase 3 trials

June 4, 2019
Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial

Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …

News
janssen_latest_logo_on_sign_closer

Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

June 3, 2019
Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …

News
janssen_latest_logo_on_sign

Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup

May 30, 2019
Research and Development Janssen, darzalex, pharma

Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …

News
spravato

Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression

May 23, 2019
Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression

Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …

News

Insider Interview: Paving paths in prostate cancer

May 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …

Feature

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023